The case for & against
Bull & Bear analysis
CBDMD, Inc. (NYSE: YCBD) is a leading provider of cannabinoid products, specializing in hemp-derived CBD oils, capsules, topicals, and beverages under its OASIS brand. The company operates within the rapidly evolving consumer wellness industry and is strategically positioned to leverage its expertise as it navigates a complex regulatory landscape. CBDMD has focused on operational improvements and acquisition integrations to bolster its market presence, particularly with the recent acquisition of Bluebird Botanicals, and aims to capitalize on the growing functional beverage market.
Bull says
- ↑Q2 revenue $5.6M (+19% YoY, +12% QoQ) driven by core operations
- ↑OASIS beverage segment targets $4B+ market, with new TN and MN distribution
- ↑Bluebird Botanicals integration to become earnings accretive from Q3
- ↑Proposed Senate bill offers regulatory clarity for full-spectrum CBD stability
- ↑Balance sheet bolstered by $4M dividend elimination and improved capital structure
- ↑Strong quality factors, undervaluation by book-to-price, positive analyst revisions
Bear says
- ↓Q2 operating loss of $801K (vs $486K loss YoY) highlights inefficiencies
- ↓Net cash burn of $723K in Q2 raises liquidity concerns
- ↓Heavy reliance on D2C sales (78%) exposes revenue to channel risk
- ↓Ongoing state-level regulation increases compliance costs and revenue uncertainty
- ↓Weak profitability factors and negative earnings yield signal poor return generation
- ↓Lack of institutional interest and small-cap vulnerability may boost volatility
Investment themes with YCBD
Drug development driving global healthcare solutions
Stocks with highest short interest
Earnings Call · Q2 2026 · Mgmt. Guidance
Transcript signals
Bull points
- The second quarter of fiscal 2026 was another step forward for CBDMD and one of the most active quarters we've had in years, both operationally and across the regulatory landscape we operate in.
- Wholesale was up 65% year-over-year, reflected continued execution in our core CBDMD brand and ongoing progress with our Oasis THC beverage brand.
- We believe the long-term opportunity is significant, and we believe CBDMD's years of investment in manufacturing, quality, safety, and clinical research positions the company as a trusted, evidence-based supplier of choice as this channel develops.
Bear points
- As expected, the acquisition was a drag on earnings during the second quarter, where we absorbed transition costs and integration expenses without the full benefit of a full quarter of Bluebird revenue.
- That said, Bluebird turned the corner in March and began generating positive contribution, and we expect to flip that into positive for both top-line earnings and earnings in the third quarter as we roll out additional products and capture costs and revenue synergies.
- Changing rules across multiple states has driven ongoing packaging changes, repacking costs, and new testing requirements, each carrying real expenses and creating confusion at the customer level.